Fact.MR – A Market Research and Competitive Intelligence Provider: Rising prevalence of cancer and increasing compliance of chemotherapy drugs are translating into demand for effective chemotherapy-induced nausea and vomiting treatment options.
Hospitals To Remain a Top Contributor in US$ 5.7 Bn Chemotherapy Induced Nausea and Vomiting Treatment Market
The Fact.MR market study on chemotherapy-induced nausea and vomiting (CINV) treatment market highlights key developments across various segments including form, drug class, emetogenic risk, and distribution channels. The study projects hospitals for CINV treatment to remain the fastest-growing distribution channel.
Fact.MR – A Market Research and Competitive Intelligence Provider: Rising prevalence of cancer and increasing compliance of chemotherapy drugs are translating into demand for effective chemotherapy-induced nausea and vomiting (CINV) treatment options. Considering this, Fact.MR projects the global chemotherapy-induced nausea and vomiting treatment market to grow at a positive 6% CAGR, reaching US$ 5.7 Bn in 2031.
The World Health Organization (WHO) identifies cancer as one of the biggest social and economic burdens on humanity. Growing incidence of cancer cases is resulting in increasing number of patients requiring chemotherapy.
Anemia, sore mouth, nausea, vomiting, and hair loss are common side effects of chemotherapy that have a severe impact on the daily life of patients, resulting in high demand for CINV treatment options.
Consistent innovations in drug delivery systems, along with the availability of combination therapies for treating chemotherapy-induced nausea and vomiting are further augmenting the market growth.
Request a report sample to gain comprehensive insights at
https://www.factmr.com/connectus/sample?flag=S&rep_id=6867
In order to address the rising demand, market players are investing in research and development to offer more effective and accessible solutions. This is indicative of lucrative growth prospects for the market in the upcoming decade.
As per Fact.MR, the U.S. is anticipated to dominate the North America chemotherapy-induced nausea and vomiting treatment market, accounting for 86% of the regional sales by 2031. The presence of leading market players and well-established healthcare infrastructure will continue boosting sales of chemotherapy-induced nausea and vomiting treatment through 2031.
“Availability of CINV treatment drugs through online retail channels, coupled with government-backed reimbursement plans in developed nations will continue shaping the demand outlook for chemotherapy-induced nausea and vomiting treatment market in the forthcoming years,” says the Fact.MR analyst.
Key Takeaways from Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Survey
- Based on form, 5-HT3 receptor antagonists are projected to account for 42% of the total revenue in the chemotherapy-induced nausea and vomiting treatment market.
- Sales of injectables for chemotherapy-induced nausea and vomiting treatment are anticipated to grow at a 6.4% CAGR through 2031.
- The hospital segment is estimated to expand at a 4.5% CAGR during the assessment period.
- The U.S. is projected to dominate the North American chemotherapy-induced nausea and vomiting treatment market, holding 86% of the market share in 2021.
- The U.K. is anticipated to dominate the European market, growing at a 6.4% CAGR, holding 20% of the European market share.
- Germany will account for 17% of the European chemotherapy-induced nausea and vomiting treatment market.
- China will emerge as an attractive market, due to increasing awareness regarding CINV treatment in Asian countries.
Growth Drivers:
- Easy availability of chemotherapy-induced nausea and vomiting treatment drugs through online pharmacies will foster sales in the upcoming years.
- Fast-track drug approvals will further boost sales of chemotherapy-induced nausea and vomiting treatment solutions.
- Treatment reimbursement plans in developed countries will facilitate sales of chemotherapy-induced nausea and vomiting treatment drugs and equipment.
Restraints:
- Regulations on accessibility and availability of CINV drugs might stunt market growth.
- Loss of brand exclusivity of generic drugs might hamper sales of CINV treatment solutions.
To learn more about Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market, you can get in touch with our Analyst at
https://www.factmr.com/connectus/sample?flag=AE&rep_id=6867
Competitive Landscape
Key players operating in the global chemotherapy-induced nausea and vomiting treatment market are focusing on new product launches to meet the growing demand for the same. Apart from this, acquisitions, collaborations, and mergers will remain widely used growth strategies among players in the market. For instance, in January 2019, GSK acquired TESARO Inc., a biopharmaceutical company specializing in oncology, for a cash consideration of US$ 5.1 Bn.
Leading Players in the Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market Include:
- Kyowa Kirin, Inc.
- Pfizer Inc.
- GlaxoSmithKline plc.
- AbbVie Inc. (Allergan plc)
- Merck & Co., Inc.
- Bausch Health Companies Inc.
- Novartis AG
- Ono Pharmaceutical Co., Ltd.
- Camurus AB
- Heron Therapeutics, Inc.
More Valuable Insights on Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market
Fact.MR provides an unbiased analysis of chemotherapy-induced nausea and vomiting (CINV) treatment market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global chemotherapy-induced nausea and vomiting (CINV) treatment market with a detailed segmentation on the basis of:
Form:
- Injectables
- Oral
- Transdermal Patches
Drug Class:
- 5-HT3 Receptor Antagonists
- Neurokinin-1 Receptor Antagonists
- Corticosteroids
- Cannabinoids
Emetogenic Risk:
- Highly Emetogenic Chemotherapy (HEC)
- Moderately Emetogenic Chemotherapy (MEC)
- Low Emetogenic Chemotherapy (LEC)
Distribution Channel:
- CINV Hospitals
- Cancer Research Institute
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- MEA
Key Questions Covered in the Market Report
- The report offers insight into chemotherapy-induced nausea and vomiting treatment market demand outlook for 2021-2031
- The market study also highlights projected sales growth for chemotherapy-induced nausea and vomiting treatment market between 2021 and 2031
- Chemotherapy-induced nausea and vomiting treatment market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Chemotherapy-induced nausea and vomiting treatment market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain –
Oral Chemotherapy Market- The increase in the number of cancer patients is a major factor driving the global growth of the oral chemotherapy market. In addition, doctors' preference for oral chemotherapy over intravenous oral chemotherapy is expected to boost revenue growth in the oral chemotherapy market. Simultaneously, the continual introduction of new oral chemotherapy medications for the treatment of cancer is boosting oral chemotherapy's acceptance in the global market. Furthermore, increased investment by prominent manufacturers in the development of novel chemotherapy medications will give a significant opportunity for the oral chemotherapy market to grow.
Cancer Profiling Market- The global cancer profiling market is predicted to grow significantly, as the demand for precision medicine and high-quality oncology care grows. With the worldwide cancer burden expected to rise, patients and doctors alike are hurrying to find highly effective and long-lasting cancer diagnostics, driving a slew of new service providers to enter the market. Smart technology, nanomedicine, and automation are being used efficiently by key solution providers to speed up diagnostic processes. Patients have been able to seek prompt treatment for their tumors thanks to the reduction in testing timelines that yield accurate results.
Cancer Immunotherapy Market- According to a recent analysis issued by Fact.MR, there is a disparity in the distribution of cancer immunotherapy between developing and developed countries. Individuals in the United States are more likely to seek cancer diagnostics as a result of the high frequency of knowledge-based awareness efforts. Developing countries such as Brazil and Argentina, on the other hand, lack basic cancer treatment techniques. Cancer immunotherapy markets in developing Asia Pacific countries with high population density and average penetration of quality treatment has high potential.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR